Dianna L Boyer, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10701 Alliance Dr Ste A, Camby, IN 46113 Phone: 317-856-7083 Fax: 317-856-7332 |
Dr. Eric L Wymer, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 10701 Alliance Dr, Camby, IN 46113 Phone: 317-856-7083 Fax: 317-856-7332 |
Abigail Catellier, FNP-C Internal Medicine Medicare: Medicare Enrolled Practice Location: 10701 Alliance Dr Ste A, Camby, IN 46113 Phone: 317-372-7328 |
News Archive
We all know people who are able to roll with life's punches, while for others, every misfortune is a jab straight to the gut. Research examining this issue has found that although most people require significant adversity to become depressed - the death of a loved one, say, or getting fired - roughly 30 percent of people with first-time depression and 60 percent of people with a history of depression develop the disorder following relatively minor misfortunes.
A new targeted drug demonstrated its ability to control metastatic gastrointestinal stromal tumor, an uncommon and life-threatening form of sarcoma, after the disease had become resistant to all existing therapies, report investigators at Dana-Farber Cancer Institute who led the worldwide clinical trial.
Critical Path Institute announced today that the Biomarker Qualification Program at the Center for Drug Evaluation and Research in the U.S. Food and Drug Administration issued a positive response to the Letter of Intent developed by C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium, for a panel of four safety biomarkers of acute drug-induced skeletal muscle injury.
Being young doesn't mean you are immune to a stroke. You may feel healthy; you may be 18 or a vigorous 50. And yet you could be more vulnerable than you know. That could be because of the role played by silent risk factors in stroke.
The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.
› Verified 9 days ago